Thyas’ platform: We Regenerate Your Immune System

Thyas owns proprietary iPSC-derived immune cell platform and continuously generates Immune cell products

Various Immune Cells derived from Allogeneic iPSC

iTCR-T (iPSC-derived TCR-T)
iCD4-ILC (iPSC-derived CD4+ Innate Lymphoid Cell)

Thyas’ next-gen iTCR-T

Thyas develops personalized iTCR-T for the next-generation iTCR-T to target personalized antigens (including neoantigens) and expand the patient applicability
  1. 1Selection of Activated T cells with a specific marker
  2. 2Quick acquisition of selected TCRs
  3. 3Personalized iPS-TCR-T (2nd Generation iTCR-T)


iPS-T Eliminates Tumor Cells while Proliferating

Exhausted parental T cells
Black:Parental T Cell Clone (Exhausted)
Green:Antigen X positive tumors
                   (Black cells can not kill green cells well)

Black:iPSC-derived CD8a+b+T cells (Rejuvenated)
Green: Antigen X positive tumors
                   (Black cells kill green cells while

Molecular Therapy (2021), doi: j.ymthe.2021.05.016.

iPS-T Demonstrates Specific Cytotoxicity against Tumor Cells

iPS-Ts only attack the targeted cancer cells.

Red : iPS-T specific to antigen X
Green: Tumor cells NOT expressing antigen X
                    (iPS-T patrols but does not attack
                    the tumor cells)

Red : iPS-T specific to antigen X
Green: Tumor cells expressing antigen X
                    (iPS-T attacks and eliminates
                    the tumor cells)

Cell Stem Cell | (2018) 23:1–9 |

iPS-T is CD8α+β+ T cells

  • iPS-T expresses CD8α+β+.
  • iPS-T has high avidity to target antigens (adaptive immunity) while CD8α+α+ T cells have low avidity to them (innate immunity).


Strong TCR signals
for antigen specific cytotoxicity


Insufficient TCR signals
for antigen specific cytotoxicity

Cell Stem Cell | (2018) 23:1–9 |

iPS-T Regains Naive T Cell Phenotype

  • Memory T cells play a key role in immune surveillance and long-term immunity.
  • It is reported clinical efficacy of immune checkpoint inhibitors, or CAR-T has a strong positive correlation with the proportion of memory/naive T cells in patients’ body.

iPS-T is Proliferative as Naïve T cells

  • iPS-T has longer telomere than parental T cells.

Elongation of iPS-T‘s telomere
Correlation between the efficacy of T cell therapy
and the telomere length is reported.

Nat Rev Cancer | (2008) 8: 299–308 |

iPS-T‘s high ability of proliferation
Exhausted T cells do not proliferate well,
while iPS-T shows massive growth
as naïve T cells do.

iPS-T Reduces Expression of Exhaustion Markers

  • iPS-T has no/low expression of exhaustion markers unlike patients’ exhausted T cells.

Patient’s exhausted T cell
When immune checkpoint receptors on
T cells are activated, cytotoxic responses of
T cells are suppressed.

As iPS-T cells express no/less
check points receptors,
potent cytotoxic responses
against tumor cells are regained.


※Please scroll left and right to see.